Hemogenyx Pharmaceuticals Share Price (HEMO)

[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx Pharmaceuticals Plc LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -0.04 -2.0% 1.96 6,957,393 10:01:02
Bid Price Offer Price High Price Low Price Open Price
1.92 2.00 2.00 1.96 2.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.12 11
Last Trade Time Trade Type Trade Size Trade Price Currency
13:12:57 O 154 1.958 GBX
Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Motif Bio (MTFB), Bermele (BERM)

Hemogenyx Pharmaceuticals (HEMO) Latest News

Hemogenyx Pharmaceuticals News

Date Time Source Headline
02/9/202121:44ALNCTRADING UPDATES: Challenger Energy hails Saffron-2 well; SDCL placing
02/9/202107:00UKREGHemogenyx Pharmaceuticals PLC U.S. Approval of Monoclonal Antibody Patent
26/7/202107:00UKREGHemogenyx Pharmaceuticals PLC Appointment of Business Advisor & Board..
02/7/202111:23RNSNONHemogenyx Pharmaceuticals PLC Corporate Presentation
25/6/202115:32UKREGHemogenyx Pharmaceuticals PLC Result of Annual General Meeting
16/6/202116:40UKREGHemogenyx Pharmaceuticals PLC Second Price Monitoring Extn
16/6/202116:35UKREGHemogenyx Pharmaceuticals PLC Price Monitoring Extension
15/6/202112:41UKREGHemogenyx Pharmaceuticals PLC Changes to 2021 AGM Arrangements
15/6/202111:06UKREGHemogenyx Pharmaceuticals PLC Second Price Monitoring Extn
15/6/202111:00UKREGHemogenyx Pharmaceuticals PLC Price Monitoring Extension
More Hemogenyx Pharmaceuticals News
Hemogenyx Pharmaceuticals Investors    Hemogenyx Pharmaceuticals Takeover Rumours

Hemogenyx Pharmaceuticals (HEMO) Discussions and Chat

Hemogenyx Pharmaceuticals Forums and Chat

Date Time Title Posts
20/9/202113:23HEMO6,615
12/9/202120:32Hemogenyx- Official Thread 236
09/6/202115:22Hemogemyx - nomoderated25
03/6/202114:50Hemogenyx - 2021 Entry to clinical status281
18/4/202100:43HEMO 2020/21 Discussion MODERATED3,215

Add a New Thread

Hemogenyx Pharmaceuticals (HEMO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:12:581.961543.02O
12:09:331.9210,000192.16O
11:49:261.9681215.92O
11:46:141.927,286140.01O
11:38:011.9210,000192.16O
View all Hemogenyx Pharmaceuticals trades in real-time

Hemogenyx Pharmaceuticals (HEMO) Top Chat Posts

DateSubject
20/9/2021
09:20		Hemogenyx Pharmaceuticals Daily Update: Hemogenyx Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 2p.
Hemogenyx Pharmaceuticals Plc has a 4 week average price of 1.75p and a 12 week average price of 1.73p.
The 1 year high share price is 13.45p while the 1 year low share price is currently 1.63p.
There are currently 546,415,988 shares in issue and the average daily traded volume is 8,308,685 shares. The market capitalisation of Hemogenyx Pharmaceuticals Plc is £10,709,753.36.
Read Full Thread
Reply
24/8/2021
23:35		phil2003: Thats me already in profit here. Please see chart showing when the HEMO share price was “high” earlier this year and then dipped alot lower than that price per share, earlier this month. I bought my shares when prices were “low” and will sell them back when prices are again what experts call relatively “high” later this year, fyi.. this is how I make money. Thankyou
Read Full Thread
Follow
Reply
20/7/2021
08:57		burtond1: Much in the pipeline and negotiations with 'famous' names are ongoing for @HemogenyxPharma"We're about making drugs to treat patients, save lives & everything else will follow...including the share price"#HEMO CEO @vmsandler explains all to @TMSreachhttps://total-market-solutions.com/2021/07/hemogenyx-pharmaceuticals-3/
Read Full Thread
Follow
Reply
05/7/2021
10:45		chimpychops81: Are you saying the drugs won’t get to clinical trials? If they do are you saying the share price won’t go up? Come on oh wise one... tell me how HEMO share price doesn’t go up once the action starts? I’d like to hear this!
Read Full Thread
Follow
Reply
25/6/2021
11:12		chimpychops81: So HEMO is currently completing IND enabling studies now for the SAFE HEMO CAR T with PENN and Mr Tachlac. The purpose of IND-enabling studies is to secure approval to conduct the first-in-human clinical trials with a new drug. An IND application contains information on pharmacology and toxicology, manufacturing (e.g., composition, production, stability, etc.), human clinical study protocols, and investigator information. I wonder how much they've got through so far? Hope they're no track to submit the app by the end of the Summer. What sort of effect would an RNS confirming IND app submission to FDA have on the HEMP share price do you think Badger? Are you excited? I personally also expect Vlad to sort out a working partnership with GlobalCo going forward up to AND possibly through clinical trials. This news cant be too far off now as CDX needs to move to clinical stage like CAR T. Again, how would you see an update of this nature effecting share price Badger? The disappearing GlobalCo returning with vengeance? "GlobalCo II. Return of the Big Pharma" Going clinical is the ultimate start of a new era for HEMO. However, I see the above two stages over the next couple of weeks/months really driving HEMO to a much stronger valuation to reflect its IP, big Pharma partnerships and imminent clinical testing.
Read Full Thread
Follow
Reply
23/6/2021
10:12		justhereforhemo: Morning all, Badger yes your right, the money is all accounted for, so whats the point? They have said they have enough for now and when Vlad was deciding how much of the CLN money to keep he allocated enough to see him though the year. You dont run a business by forecasting the years budget, raising the cash for it then deciding to just go and raise another 3mil just to sit in the bank. In terms of CAR-T yes your spot on most of the cash is for clinical trials, 100% comfortable with the CAR-T side. Orgenesis - Its not due until November and by then the share price will be multiples so yea, not an issue at present. CDX Licence, was forecast at 900k and Global Co continuing to fund the CDX work as per status quo, not expected to have to pay anything up front and IMO when it does happen it will be an equity stake in Hemo anyway,I personally would love to see global co taking shares in exchange for the IP and for me is the most likely scenario. Pay Penn work? Its a sponsored agreement, here read up here https://www.parkerici.org/research-institution/penn-medicine/ From what I can understand they are covering the work of Dr June and his team but wont pay for things like IND applications or external fees hence the requirement for the 500k and 5mil. The bulk of the expenses for 2 of the biggest programs CAR-T and CDX are being borne by much wealthier partners, CAR-T appears to be strings free but CDX comes at a cost, a major discount on final licencing. CBR - Some of the money is allocated to this, we really dont know who they are working with, who is paying what, at what stage they are, nada. Kept in the dark here. I am not saying they wont do a raise throughout the year, they COULD as it will be authorised in the AGM, but if they do they have zero need to do it any time soon and there are so many things that they could start RNSing to boost the share price there is zero need to do a placing at these levels. Given the fact that they can only issue a certain number of shares in a given financial year without returning for a subsequent GM and potentially issuing an expensive prospectus do you think its a better financial decision to blow your load at 2.5p and raise 5mil cash or wait until after the good news is out and issue the same number of shares at 10p and raise 20mil? Honestly if we had not just gone through 6 months of funding nightmare with Vlad literally just securing ~10mil CLN free I would agree with you but fact is just a month ago he handed back 1.6mil he said he did not need and with current share price would only be able to raise slightly more than that.
Read Full Thread
Follow
Reply
18/6/2021
12:05		justhereforhemo: As announced on 5 January, 2021 the company has entered into a Master Translational Research Services Agreement ("Agreement") with the University of Pennsylvania ("Penn"). The goal of the Agreement is to advance HEMO-CAR-T developed by the Company toward clinical trials. -- Research the last MTRSA from Penn before saying this is not good. The Company has initiated the process of engaging contract manufacturing organizations for product development and manufacturing of DNA plasmids, viral vectors and HEMO-CAR-T cells under Current Good Manufacturing Practices ("CGMPs") to support Phase I clinical trials. • The development phase of the Company's collaboration with a leading global pharmaceutical company for the development of its CDX antibody product candidate resulted in the selection of a clone of the antibody that is ready for investigational new drug ("IND") application-enabling studies, a significant step toward clinical trials The Company's patent applications designed to protect its intellectual property progressed during the year and should begin to bear fruit in the near future. An additional composition of matter patent application (covering novel sequences of the antibodies discovered and validated by the Company in collaboration with GlobalCo) is expected to be filed following completion of the GlobalCo collaboration agreement. -- We have the initial patent, expect licencing agreement then ANOTHER patent. The Company's subsidiary in Belgium, Hemogenyx-Cell SPRL, has been considering plans with a number of potential Belgian-based partners, including Orgenesis, Inc. - the provider of funding to Hemogenyx-Cell and also to Immugenyx in a separate agreement through convertible loans - regarding key building blocks for the path through development towards clinical trials of Hu-PHECs, including the establishment of a cell bank. The Company has been developing a new cell therapy platform which the Company refers to as CBR, the essence of which is the programming of immune cells using a novel type of modifiable synthetic receptor to destroy viral pathogens including SARS-CoV-2, which causes COVID-19. Not only can this type of synthetic receptor potentially combat viral pathogens, it can also potentially be modified to programme immune cells to destroy malignant cells causing cancer. The novel synthetic receptor has no connection to, and does not resemble, any known or widely used CARs (e.g., HEMO-CAR-T), and the Directors are not aware of any direct competitor for this product candidate at this time. Hemogenyx Pharmaceuticals is now engaged in preclinical validation of two CBR-based product candidates: one for the treatment of COVID-19, and the other for the treatment of an undisclosed type of cancer.
Read Full Thread
Follow
Reply
11/6/2021
10:23		chimpychops81: CLNs are done Badger. Probably time to move on. Are you shorting if you believe HEMO will move down from here? PENN currently completing IND enabling studies. They will submit an IND app to FDA and will approved at some point. What’s the share price then? HEMO come back to confirm in a collab with Eli on CDX through to trials? What’s that do to the SP? CBR has 2 product candidates already that are moving through pre clinicals. A positive update on those and the share price Tanks? A lupus partner (J&J or Eli) announces a new candidate developed on our lupus disease modelled mice so we are due royalties? Will this hammer the share price down also? All of these things are pretty likely to happen. I do not believe that you believe your own BS. You’re apparently too smart for that... or so I thought.
Read Full Thread
Follow
Reply
08/6/2021
14:20		justhereforhemo: Badger, first off,the MMs were churning alot of shares, but last day or two it looks like most of the "sells" end up being short positions when they are reported later in the day or the next day so any rinse and repeat is likely to fill orders not churn placing shares, but its irrelevant as big buy orders the MMs drop the price to fill, big placing sell and MMs drop the price aswell. In terms of Mint and the placing shares, again this is irrelevant, but no, its my understanding that Mint did NOT get any of the shares from the last conversion, HOWEVER thats not to say they didnt have millions of shares from previous conversions. And again totally irrlevant as clearly many who took part in the placing flipped their shares as soon as they had the chance, just like mint would have making them no better than Mint. Finally, yes very dissapointed that Vlad didnt just repay more of the CLNs and go for a smaller placing, that was the plan but there was so much cash offered because of the discount that he took it. Again totally disagree with the massive discount, it was far too large, I would have been happy with a 1.9p share price which is what I thought it was going to be being a 10% discount on the lowest closing bid from 3 previous days. It may have taken the pressure off hemo for a long time but I still do not agree with the exact details. All that aside, its pretty irrelevant right now, the CLNs are gone, any that are sold are either shares that are already on the share register IE not CLNs that can be converted at a cheaper price, or they are borrowed and shorted shares that must be replaced with other shares from the register... Does not change the fact that Hemo is currently 20mil mCap with a much better portfolio than last year when they were 50mil mcap with no funds.
Read Full Thread
Follow
Reply
08/6/2021
03:29		badger60: ChimpyUnless MadVlad comes up with something spectacular, especially concerning future funding, I believe that the share price here will struggle to go forward. Everything is still pre clinical and unproven, and time is very much against Hemo with it's limited resources and cash burn. Bearing in mind that over 93% of bio/pharma product development fails, and MadVlad has at least 5-7 years work ahead of him before they can produce a commercially viable product(and that's if it works), I would argue that the share price from here on in will be on a down trend, especially when the MMS stop playing with it because the volume dries up.
Read Full Thread
Follow
Reply
28/5/2021
11:17		justhereforhemo: Bahamarama, do you believe that the Death Spiral Finance would have occurred had the negative posting, dumping and damage to the share price had not happened? The key point is that those, like myself, who fought very very hard to shut down those trying to damage the share price back before the CLNs were ever drawn down knew that CLNs carried a risk, but the risk was mitigated by a high share price The actions of the few contributed to the self fulfilling prophecy of the hard core derampers. Did they call it correctly or did they help to bring about the situation where the Death Spiral became a reality? Nobody can say for 100% sure either way,I for one cannot say it never would have happened anyway, but the company stood a much better chance of not being damaged had the CLNs been drawn with the share price 10p+ and a MCap of 50-60mil. That said when it became clear that the CLNs were being shorted and dumped, I and others stopped defending them or the company. I activly switched from defending the company to contacting Hemo to try and warn them about what was becoming a reality and begging them to cancel and repay. CLNs were a mistake, had purple and badger posted just a few reasonable posts calling out the potential risks, calling on past experiences etc then there is an excellent chance I would have reduced my position back then. Healthy debate is good, but it goes both ways, up until a few days ago anyone posting a positive view of hemo on LSE was getting jumped on and told how the market was about to be swamped and driven to sub 1p.
Read Full Thread
Follow
Reply
Hemogenyx Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
HEMO
Hemogenyx ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210920 12:42:38